Trials / Completed
CompletedNCT02314273
Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL
Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Shanghai Children's Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.
Detailed description
Group A：patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL Group B：control group
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhIL-11 | patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2014-12-11
- Last updated
- 2014-12-11
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02314273. Inclusion in this directory is not an endorsement.